Highest development stage: Phase 1 for inhalation (since 2013)

Development status: Approved, off-patent

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive and Gram-negative bacteria

Additional information: Semisynthetic, derived from dibekacin. Marketed in Japan for systemic use to treat MRSA infections, developed for inhalation in the US (since 2018)